{"id":"s-ketamine-0-75","safety":{"commonSideEffects":[{"rate":null,"effect":"Dissociation/emergence reactions"},{"rate":null,"effect":"Increased heart rate"},{"rate":null,"effect":"Increased blood pressure"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"S-Ketamine blocks NMDA receptors on glutamatergic neurons, which interrupts excitatory neurotransmission and produces dissociative anesthesia. The S-enantiomer is approximately 3-4 times more potent than the R-enantiomer at the NMDA receptor and is associated with faster onset and offset of action, making it suitable for clinical anesthesia and acute pain management.","oneSentence":"S-Ketamine is the active S-enantiomer of ketamine that acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor to produce rapid-onset anesthetic and analgesic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:06:27.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Induction and maintenance of general anesthesia"},{"name":"Acute pain management"}]},"trialDetails":[{"nctId":"NCT06538285","phase":"PHASE2","title":"Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV","status":"RECRUITING","sponsor":"Nicky Mehtani, MD, MPH","startDate":"2025-03-04","conditions":"Methamphetamine Use Disorder","enrollment":12},{"nctId":"NCT05752409","phase":"NA","title":"Comparison of Esketamine-Propofol and Fentanyl-Propofol","status":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2021-10-08","conditions":"Hemodynamics","enrollment":120},{"nctId":"NCT02994173","phase":"PHASE4","title":"Dose-response of Ketamine in Patient Controlled Analgesia in Orthopaedic Surgery Patients","status":"COMPLETED","sponsor":"Turku University Hospital","startDate":"2017-02-01","conditions":"Pain, Postoperative","enrollment":100},{"nctId":"NCT01275547","phase":"PHASE2, PHASE3","title":"The Analgesic Effect of Combined Treatment With Intranasal S-ketamine and Intranasal Midazolam","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2011-01","conditions":"Analgesia, Patient-controlled, Spinal Stenosis","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ketanest-S"],"phase":"marketed","status":"active","brandName":"S-Ketamine 0.75","genericName":"S-Ketamine 0.75","companyName":"Turku University Hospital","companyId":"turku-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S-Ketamine is the active S-enantiomer of ketamine that acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor to produce rapid-onset anesthetic and analgesic effects. Used for Induction and maintenance of general anesthesia, Acute pain management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}